Peripheral and central nervous system distribution of the CGRP neutralizing antibody [I] galcanezumab in male rats.

Authors:
Kirk W Johnson
Kirk W Johnson
University of Colorado at Boulder
United States
Victor J Wroblewski
Victor J Wroblewski
Medical University of Innsbruck
Austria
Michael P Johnson
Michael P Johnson
Lilly Research Laboratories

Cephalalgia 2019 Apr 19:333102419844711. Epub 2019 Apr 19.

1 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.

Objective: The objective of this investigation was to examine the distribution of galcanezumab and a control immunoglobulin 4 antibody containing the same constant regions as galcanezumab, into peripheral and central tissues.

Methods: Galcanezumab and a control immunoglobulin 4 antibody were radioiodinated with Iodine-125 to specific activities of 0.11 mCi/mg and 0.16 mCi/mg, respectively. At 24, 72, and 168 hours following subcutaneous injection of either antibody (4 mg/kg), cerebrospinal fluid and plasma were obtained followed by saline perfusion to remove residual blood and collection of selected tissues for determination of Iodine-125 content by gamma counting.

Results: The peak plasma levels of Iodine-125 galcanezumab and Iodine-125 control immunoglobulin 4 were observed at 72 hours and remained high at 168 hours post-dose. The rank order of tissue levels was dura mater = spleen > trigeminal ganglia ≫hypothalamus = spinal cord = prefrontal cortex = cerebellum. Iodine-125 galcanezumab levels in peripheral tissue (dura mater, spleen, and trigeminal ganglia) averaged 5% to 11% of plasma, whereas all of the central nervous system (CNS) tissue levels and the cerebrospinal fluid levels were < 0.4% of plasma. Distribution of the antibodies into the dura mater and the trigeminal ganglia was similar to that observed in the spleen and significantly greater than exposure in the brain or spinal cord.

Conclusions: The central levels of galcanezumab were relatively low, which would favor the dura mater and trigeminal ganglia as sites of action for its observed clinical efficacy. However, a central site of action cannot be excluded.

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0333102419844711
Publisher Site
http://dx.doi.org/10.1177/0333102419844711DOI Listing
April 2019
3 Reads

Publication Analysis

Top Keywords

control immunoglobulin
12
immunoglobulin antibody
8
cerebrospinal fluid
8
iodine-125 galcanezumab
8
nervous system
8
galcanezumab control
8
peripheral central
8
168 hours
8
central nervous
8
tissue levels
8
galcanezumab
6
iodine-125
5
levels
5
residual blood
4
peripheral tissue
4
perfusion remove
4
remove residual
4
levels peripheral
4
blood collection
4
hours subcutaneous
4

References

(Supplied by CrossRef)

Similar Publications